FDA Approves GSK's Blujepa
ReutersMar 25, 2025 4:04 PM
March 25 (Reuters) - FDA:
FDA APPROVES GSK'S BLUJEPA- WEBSITE
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Should You Invest in the “Magnificent Seven” in 2026? One Stock or All of Them?
TradingKey - The Magnificent Seven defined markets in 2024 and remained at the heart of the 2025 story. Collectively, they have unparalleled control over AThe Magnificent Seven includes Nvidia (NVDA), Apple (AAPL), Alphabet (GOOG) (GOOGL), Microsoft (MSFT), Amazon (AMZN), Meta Platforms (META), andTradingKey
2 hours ago
January CPI Revives Rate-Cut Hopes; Gold and Silver Rebound, But Is the Bull Run Intact?
TradingKey - During Friday's US session, spot gold surged back above $5,000 to close at $5,043, while silver resumed its rally, breaking through the $75 mark to peak near $79 before closing at $77.43. This movement was primarily driven by data from the U.S. Bureau of Labor Statistics that significanTradingKey
Sun, Feb 15
SpaceX IPO with Dual-Class Shares: Will Musk Secure the 25% Voting Control Denied by Tesla?
TradingKey - SpaceX is preparing for an IPO this year. According to foreign media reports, SpaceX is considering a dual-class share structure for its IPO, which would grant specific shareholders extra voting rights. In other words, Elon Musk could maintain absolute control over the company even if hTradingKey
Sat, Feb 14
Bitcoin Price Prediction 2029-2035: Institutional Accumulation and the U.S. Treasury’s Strategic Reserve Pivot
Explore the 2026 Bitcoin landscape: From the U.S. Strategic Reserve and Michael Saylor’s $75B war chest to Cathie Wood’s 2030 forecast. Is BTC the new Digital Gold?TradingKey
Fri, Feb 13
Is SaaS Dead? The Truth Behind the Software Meltdown, the Missing Floor, and the Peak That’s Not Coming Back
TradingKey - A trillion dollars just vanished from software stocks—this piece breaks down who AI is really killing, who quietly benefits, and why cheap SaaS may be the biggest value trap of this cycle.TradingKey
Thu, Feb 12
